We discovered that JAK2-mutated cancers displayed upregulated expression of immune checkpoint molecules (such as PDCD1, CD274, CTLA4, and TIGIT) compared with JAK2-wild tumors (Fig. 2I–L). This evidence concerns the gene JAK2 and cancer.